Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07014293 · ClinicalTrials.gov registry record · NA
Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors
A NA study, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 254
- Enrollment target
NCT07014293: Recruiting NA study, sponsored by Massachusetts General Hospital.
NCT07014293 is a NA study that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 254 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07014293, a NA study, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 254 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if a mind body resilience group program can help increase lymphoma survivors' ability to cope with and manage the challenges that come with the transition into early post treatment survivorship.
Primary Outcome
The Measure of Current Status Scale (MOCS-A) measures coping processes on 4 domains: ability to relax, recognize stress, elicit support, and restructure thoughts. It is a 13-item scale where each item is measured on a 0-4 scale.
Interventions
- OTHER Enhanced Usual Care
- OTHER SMART3RP-Lymphoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2030-07-01 |
| Phase | NA |
What NCT07014293 shows while recruiting
NCT07014293 is an interventional study that assigns participants to a tested intervention. The registered 254 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 2 interventions - of which Enhanced Usual Care is the first listed.
NCT07014293 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07014293 about?
NCT07014293 is a clinical study titled "Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors". The goal of this clinical trial is to learn if a mind body resilience group program can help increase lymphoma survivors' ability to cope with and manage the challenges that come with the transition into early post treatment survivorship.
What is the current status of trial NCT07014293?
This trial is currently recruiting. It is a NA study. The enrollment target is 254 participants. The study started on 2026-07-01. Estimated completion is 2030-07-01.
What interventions are being tested in trial NCT07014293?
The interventions under investigation include: Enhanced Usual Care (OTHER), SMART3RP-Lymphoma (OTHER).
Who is sponsoring clinical trial NCT07014293?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07014293's enrollment target sits among peer trials
254 407th of 2000 higher than 1,594 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04390737 · 254 participants · Phase 1
Evaluate the Safety and Clinical Activity of HH2853
- NCT04677647 · 254 participants · NA
OurChild: A Health IT Solution to Reduce Minority Health Disparities
- NCT05503797 · 254 participants · Phase 2
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- NCT06167317 · 254 participants · Phase 1
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI